尼可地尔治疗冠状动脉慢血流的临床效果

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Nicorandil in the treatment of coronary slow flow (CSF), thus providing reference for more effective treatment in CSF patients. Methods A total of 126 patients who underwent coronary angiography (GAG) and diagnosed with CSF in Wuhan Third Hospital from December 2016 to June 2018 were selected as the research objects, and they were divided into control groups (64 cases) and combined treatment group (62 cases) according to the random number table method. Patients in the control group were given conventional treatment,while patients in the combined treatment group were given Nicorandil treatment on the basis of conventional treatment.Patients were followed up once a month for 6 months. The changes of symptoms, blood routine, inflammatory factors,homocysteine, and platelet aggregation rate of the two groups of patients before and after treatment were observed, and the incidence of adverse reactions between the two groups of patients after treatment was compared. Results After treatment, the total cholesterol, triacylglycerol, high-sensitivity C-reactive protein, interleukin-1, interleukin-6, endothelin-1, homocysteine, and platelet aggregation rate in both groups were lower than those before treatment, nitric oxide was higher than that before treatment, and the differences were statistically significant (P＜0.05). The total cholesterol, triacylglycerol, high-sensitivity C-reactive protein, interleukin-1, interleukin-6, endothelin-1, homocysteine, and platelet aggregation rate after treatment in the combined treatment group were lower than those in the control group, nitric oxide was higher than that in the control group, and the differences were statistically significant (P＜0.05). After treatment, the incidence rates of chest pain, arrhythmia and chest tightness of the two groups of patients were lower than those before treatment,and the differences were statistically significant (P＜0.05).The incidence rates of chest pain and chest tightness in the combined treatment group were lower than those in the control group,and the differences were statistically significant(P＜0.05). There was no significant difference in the total incidence rate of adverse reactions between the two groups (P＞0.05). Conclusion The combination of Nicorandil and conventional treatment can improve symptoms and inflammatory status in CSF patients more significantly.

Key words： Coronary slow flow Blood coagulation Inflammation Nicorandil

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Yuan-heng
	CHEN Xu-jiang

Cite this article:

ZHANG Yuan-heng,CHEN Xu-jiang. Clinical effect of Nicorandil in the treatment of coronary slow flow[J]. 中国当代医药, 2020, 27(16): 47-50.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I16/47

[1]	Tambe AA，Demany MA，Zimmerman HA，et al.Angina pectoris and slow flow velocity of dye in coronary arteries-a new angiographic finding[J].Am Heart J，1972，84（1）：66-71.
[2]	Arjmand N，Dehghani MR.Complete blood cell count components and coronary slow-flow phenomenon[J].Ther Clin Risk Manag，2016，12：1827-1829.
[3]	邢晓春，张寰.冠状动脉慢血流研究现状[J].吉林医学，2011，32（18）：3780-3782.
[4]	张风雷，袁燕，郑曼，等.冠状动脉慢血流现象病理生理机制及药物治疗进展[J].实用医学杂志，2014，30（23）：3727-3729.
[5]	徐朝，王胜煌.冠状动脉慢血流药物治疗研究进展[J].中国循环杂志，2015，30（1）：81-83.
[6]	王喆，宋德明，郑元喜，等.冠状动脉慢血流治疗的研究进展[J].安徽医药，2017，21（9）：1566-1569.
[7]	Gibson CM，Cannon CP，Daley WL，et al.TIMI frame count：a quantitative method of assessing coronary artery flow[J].Circulation，1996，93（5）：879-888.
[8]	姚峰，刘波，刘敏，等.尼可地尔治疗慢性缺血性心肌病患者心力衰竭的临床疗效观察[J].中国临床医生杂志，2016，44（1）：30-32.
[9]	程淑敏.尼可地尔治疗慢性缺血性心肌病患者心力衰竭的临床观察[J].药品评价，2017，14（15）：43-45.
[10]	张莉，安军，李惠娟.尼可地尔治疗心力衰竭的Meta 分析[J].中国循证心血管医学杂志，2014，6（2）：136-140.
[14]	杨中华.尼可地尔对冠状动脉慢血流患者血管内皮功能的影响观察[J].中国伤残医学，2013，21（5）：185-186.
[15]	杜静茹，杜心清，周昆林，等.冠状动脉慢血流现象应用尼可地尔治疗的临床疗效分析[J].海峡药学，2014，26（7）：114-115.
[16]	李远，郝亚逢，王涛，等.尼可地尔对冠状动脉慢血流患者血管内皮功能保护作用的临床研究[J].临床误诊误治，2017，30（1）：98-100.
[11]	Beltrame JF，Limaye SB，Wuttke RD，et al.Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon[J].Am Heart J，2003，146（1）：84-90.
[12]	Niu H，Wei Z，Zhang Y，et al.Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow[J].Exp Ther Med，2018，15（1）：904-908.
[13]	Sadamatsu K，Tashiro H，Yoshida K，et al.Acute effects of isosorbide dinitrate and nicorandil on the coronary slow flow phenomenon[J].Am J Cardiovasc Drugs，2010，10（3）：203-208.
[17]	郭文玉，王小庆，邹春霞，等.应用微循环抵抗指数评估尼克地尔对冠脉慢血流的临床疗效[J].实用中西医结合临床，2016，16（4）：45-46.
[18]	查贸孔，刘艳秋.尼可地尔联合复方丹参滴丸治疗冠状动脉慢血流的临床疗效观察[J].中西医结合心血管病电子杂志，2017，5（13）：177.
[19]	解晓蕊，李晓莉，杨朴，等.尼可地尔联合阿托伐他汀对冠状动脉慢血流患者炎症反应、血管内皮功能的影响及安全性分析[J].现代生物医学进展，2017，17（34）：6705-6708，6726.
[20]	李铭扬，桑明，孙晓东，等.尼可地尔后处理对缺氧复氧损伤H9c2 细胞的保护作用[J].华中科技大学学报（医学版），2018，47（6）：669-673.
[21]	崔跃.尼可地尔治疗微血管性心绞痛效果观察[J].中国医药科学，2018，8（1）：250-252.